[Use of native and modified terrylitin in experimental coagulated hemothorax and purulent-fibrinous pleurisy].
D000681:Amylases / Q000627:therapeutic use* / Q000633:toxicity; D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations / Q000627:therapeutic use / Q000633:toxicity; D006491:Hemothorax / Q000097:blood / Q000188:drug therapy*; D066298:In Vitro Techniques; D010447:Peptide Hydrolases / Q000627:therapeutic use* / Q000633:toxicity; D010994:Pleura / Q000187:drug effects; D010998:Pleurisy / Q000097:blood / Q000188:drug therapy*; D011817:Rabbits; D013329:Structure-Activity Relationship
D004338:Drug Combinations; C009402:amylase, phosphates, proteases drug combinations; D000681:Amylases; D010447:Peptide Hydrolases
Primenenie nativnogo i modifitsirovannogo terrilitina pri svernuvshemsia gemotorakse i gnoĭno-fibrinoznom plevrite v éksperimente.